File No. CT/37/23-DCG(I)

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

सत्यमेव जयते

File No. CT/23/000037

To,

M/s IQVIA RDS (India) Private Limited,
Omega Embassy TechSquare Marathahalli-Sarjapur,
Outer Ring Road Kadubeesanahalli Bangalore (India) – 560103.

Sir,

With reference to your application No. GCT/CT04/FF/2023/37060 (GCT/37/23) dated 14-04-2023, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, "**A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation" Protocol no: 70033093AFL3002; Original Protocol dated 09-DEC-2022 with a total of up-to 511 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

(i) **50% sites should be Govt. sites and 50% trial subjects should be enrolled in these Govt. sites;**

(ii) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

(iii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iv) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(v) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(vi) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vii) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(viii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(ix) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

(x) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(xi) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

(xii) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiv) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xvi) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvii) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xviii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial;

(xix) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;

(xx) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, cn=RAJEEV SINGH RAGHUVANSHI, 2.5.4.20=8006260e2e84ecdfbbe23f77ade4e03c2f4904107 5a06564fe67f54b765db1cb, postalCode=[illegible], serialNumber=657F5E47D940985D8F03BDC902B0E1FE73CFA12A1A126EA94FA5701124A19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2023.07.17 12:01:38 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority

Stamp

File No. CT/37/23-DCG(I)

FORM CT-06
(See rules 22,25,26,29 and 30)
PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby permits **M/s IQVIA RDS (India) Private Limited, Omega Embassy TechSquare, Marathahalli - Sarjapur Outer Ring Road Kadubeesanahalli Bangalore (India) – 560103** to conduct clinical trial of the new drug or investigational new drug as per **Protocol no: 70033093AFL3002; Original Protocol dated 09-DEC-2022** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in Part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date ________________

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI,
2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c27 69041015a06564fe67f54b765eb1cb,
postalCode=600034, st=TAMIL NADU,
serialNumber=657[illegible]47D940985D3F033DC902[illegible] 0E1FE73CFA12A1A126EA94FA5701124A19013,
cn=RAJEEV SINGH RAGHUVANSHI
Date: 2023.07.17 12:01:51 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:
Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Milvexian
Therapeutic class:	Anticoagulant
Dosage form:	Tablets
Composition:	JNJ-70033093-ZCXa =100.0000milligram (mg) In House Specification Active
Indications:	Atrial Fibrillation

File No. CT/37/23-DCG(I)

Annexure:

Details of clinical trial site:

Sr. No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1.	Manipal Hospital, 85-86 Mysuru-Bengaluru Ring Road Junction, Bannimantap 'A' Layout, Siddqui Nagar, Mysuru – 570015, Karnataka	Institutional Ethics Committee, Columbia Asia Hospital Mysuru, 85-86 Mysuru-Bengaluru Ring Road Junction, Bannimantap 'A' Layout, Siddqui Nagar, Mysuru – 570015, Karnataka	Dr. Keshava Murthy C.B
2.	Eternal Hospital, Unit of Eternal Heart Care Centre and Research Institute Pvt. Ltd., 3A, Jagatpura Road Near Jawahar Circle, Jaipur-302017, Rajasthan, India	Eternal Heart Care Centre and Research Institute - Institutional Ethics Committee, 3A, Jagatpura Road Near Jawahar Circle, Jaipur-302017, Rajasthan, India ECR/615/Inst/RJ/2014/RR-20	Dr. Jugal Bihari Gupta
3.	Nirmal Hospital Pvt. Ltd., Ring Road, Surat, Gujarat-395002, India	Nirmal Hospital Pvt. Ltd Ethics Committee, Nirmal Hospital Pvt. Ltd., Ring Road, Surat, Gujarat-395002, India ECR/390/Inst/GJ/2013/RR-19	Dr. Atul Damodar Abhyankar
4.	Unicare Heart Institute and Research Institute, Acme Plaza, B-Wing, Near Sosyo Circle, Canal Road, Surat-395002, India	Unity Hospital Ethics Committee, Unity Trauma Centre and ICU, N-4 Janki Park Society, Aai Mata Road, Paravat Patiya, Surat, Gujarat-395010, India ECR/1226/Inst/GJ/2019	Dr. Devang M Desai
5.	Arneja Heart and Multispecialty Hospital, Plot No. 123, Ramdaspeth, Nagpur-440010, Maharashtra, India	Arneja's Institutional Ethics Committee, Arneja Heart and Multispecialty Hospital, Plot No. 123, Ramdaspeth, Nagpur-440010, Maharashtra, India	Dr. Jaspal Arneja
6.	Nil Ratan Sircar Medical College and Hospital, 138, AJC Bose Road, Kolkata-700014, West Bengal, India	Institutional Ethics Committee NRS Medical College, Nil Ratan Sircar Medical College and Hospital, 138, AJC Bose Road, Kolkata-700014, West Bengal, India	Dr .Swapan Kumar Halder
7.	Chopda Medicare and Research Centre Pvt. Ltd., Magnum Heart Institute, 3/5 Patil Lane No. 1, Laxmi Nagar, K. B.	Magna-Care Ethics Committee, Chopda Medicare and Research Centre Pvt. Ltd., Magnum Heart Institute, Canada Corner, Nashik-422005, Maharashtra, India	Dr. Manojkumar Bhavarilal Chopada

	H. Vidyalaya, Canada Corner, Nashik-422005, Maharashtra, India Chopda Medicare and Research Centre Pvt. Ltd., Magnum Heart Institute, Clinical Research Department, Flat No. 10, Laxmanrekha Apartment Behind Magnum Heart Institute, Patil Lane No. 1, Canada Corner, Nashik-422005, Maharashtra, India		
8.	Nanjappa Life Care, #5619, Gadikoppa, Sagar Road., Shivamogga-577205, Karnataka, India	Nanjappa's Institutional Ethics Committee, Nanjappa Life Care, #5619, Gadikoppa, Sagar Road., Shivamogga-577205, Karnataka, India ECR/537/Inst/KA/2014/RR-20	Dr. Narendra Jathappa
9.	Kamalnayan Bajaj Hospital, Gut no.43, Satara Parisar, Beed bypass road, Aurangabad-431010, MH, India	Ethics Committee Kamalnayan Bajaj Hospital, Kamalnayan Bajaj Hospital, Gut no.43, Satara, Aurangabad-431010, MH, India ECR/444/Inst/MH/2013/RR-20	Dr. Ajit Raghunath Bhagwat
10.	KLES Dr Prabhakar Kore Hospital & Medical Research centre, Nehru Nagar, Belagavi, Karnataka, India - 590010	Institutional Ethics Committee, KLE Academy of Higher Education and Research (KAF{ER), Belagavi, JNMC Campus, Nehru Nagar, Belagavi-590010, Karnataka, India	Dr. Prasad M R
11.	IPGME& R and SSKM Hospital, 244, AJC Bose Road, Bhowanipore, Kolkata, West Bengal-700020	IPGME& R Research Oversight Committee, IPGME& R and SSKM Hospital, 244, AJC Bose Road, Bhowanipore, Kolkata, West Bengal-700020 ECR/35/Inst/WB/2013/RR-19	Dr. Sankar Chandra Mondal
12.	Lisie Hospital, P.B. No. 3053, Kochi - 682018, Kerala	Institutional Ethics Committee, Lisie Hospital, Kochi - 682018, Kerala	Dr. Jabir Abdullakutty

13.	Medica Superspecialty Hospital 127, Eastern Metropolitan Bypass, Nitai Nagar, Mukundapur, Kolkata, West Bengal 700099	Clinical Research Ethics Committee, Medica Superspecialty Hospital 127, Eastern Metropolitan Bypass, Nitai Nagar, Mukundapur, Kolkata, West Bengal 700099	Dr. Dilip Kumar
14.	G. Kuppuswamy Naidu Memorial Hospital (A Unit of the Kuppuswamy Naidu Charity Trust for Education and Medical Relief) Accredited by National Accreditation board for Hospitals & Healthcare, Providers (NABH), Post Box No. 6327, Nethaji Road, Pappanaickenpalayam, Coimbatore-640137, India	Institutional Ethics Committee, G. Kuppuswamy Naidu Memorial Hospital, Post Box No. 6327, Nethaji Road, Pappanaickenpalayam, Coimbatore - 640137, India	Dr. Rajpal Kananaklal Abhai Chand
15.	Yashoda Hospital, Rajbhavan Road, Somajiguda, Hyderabad-500082, Telangana, India	Institutional Ethics Committee, Yashoda Academy of Medical Education and Research, Yashoda Hospital, Behind Hari Hara Kala Bhavan, S.P. Road, Secunderabad-500003, Telangana, India ECR/49/Inst/AP/2013/RR-22	Dr. Athuluri Ravi Kanth
16.	Department of Cardiology, Maharaja Agrasen Hospital West Punjabi Bagh ,New Delhi-110026	Institutional Ethics Committee Maharaja Agrasen Hospital, West Punjabi Bagh ,New Delhi-110026	Dr. Bharat Bhushan Chanana
17.	Swasthyam Super speciality Hospital, 97/98, Wardha Road, Near Sai Mandir, Vivekanand Nagar, Nagpur-440015, Maharashtra, India	Swasthyam Ethics Committee, Swasthyam Super speciality Hospital, 97/98, Wardha Road, Near Sai Mandir, Vivekanand Nagar, Nagpur-440015, Maharashtra, India	Dr. Pankaj Harkut
18.	Central India Cardiology Hospital and Research Institute, Plot No. 1, Pioneer Co-Op Housing Society, Gawande Layout, Khamla Ring Road, Opp Sawarkar Garden, Khamla, Nagpur-440015, Maharashtra, India	IEC Rughwani Child Care Centre and Hospital, 22 Sindhu Nagar, Mohanlal Rughwani Marg, Jaripatka, Nagpur, Maharashtra-440014, India	Dr. Jawahirani Anil Ramesh

19.	Bhaikaka University, Bhanubhai and Madhuben Patel Cardiac Centre, Shree Krishna Hospital and Medical Research Centre, Karamsad, Gujarat, India	Institutional Ethics Committee, Bhaikaka University, Office IEC, Department of Biochemistry, Pramukhswami Medical College, Karamsad-388325, Gujarat, India	Dr. Sunil Kumar Karna
20.	Fortis Escorts Hospital, Majitha Verka Bye Pass Road, Amritsar, Punjab-143004	Institutional Ethics Committee, Fortis Escorts Hospital, Majitha Verka Bye Pass Road, Amritsar, Punjab-143004 ECR/334/Inst/2013/RR-19	Dr. Arun Kumar Chopra
21.	Grant Medical Foundation, Ruby Hall Clinic, 40, Sassoon Road, Pune-411001, Maharashtra, India	Institutional Ethics Committee, Poona Medical Research Foundation, E-4 C to E-F, 4th Floor, Fifth Avenue Condminium, Dhole Patil Road, Pune-411001, Maharashtra, India	Dr .Purvez Grant
22.	Viveka Superspeciality Hospitals, Plot no. 1A, Naik Layout, Subhash Nagar, Nagpur- 440022, Maharashtra. India	Viveka Hospital Ethics Committee, Viveka Superspeciality Hospital & Research Centre Pvt. Ltd., Plot No. 1, Naik Layout. Subhash Nagar Road, Nagpur-440022. Maharashtra. India	Dr. Prashant Manohar Jagtap
23.	CARE Hospitals, Hi-Tech City, Old Mumbai Highway, Near Cyberbad Police Commissionerate, Hyderabad-500032	Institutional Ethics Committee, CARE Hospitals, Room No. 628, 6th Floor, Road No. 1, Banjara Hills, Hyderabad, Telangana-500034	Dr. Ashutosh Kumar

****